Aslan Pharmaceuticals commences steps to place itself in voluntary liquidation
PremiumThe FlyAslan Pharmaceuticals commences steps to place itself in voluntary liquidation
2M ago
ASLAN Pharmaceuticals Faces Nasdaq Delisting
Premium
Company Announcements
ASLAN Pharmaceuticals Faces Nasdaq Delisting
2M ago
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal
Premium
Press Releases
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal
2M ago
Aslan Pharmaceuticals plans to implement ADS ratio change
PremiumThe FlyAslan Pharmaceuticals plans to implement ADS ratio change
3M ago
Aslan Pharmaceuticals files to sell 61.9M ordinary shares for holders
Premium
The Fly
Aslan Pharmaceuticals files to sell 61.9M ordinary shares for holders
3M ago
Aslan Pharmaceuticals Amends Loan Conversion Terms
Premium
Company Announcements
Aslan Pharmaceuticals Amends Loan Conversion Terms
4M ago
Eblasakimab Shows Promise for AD Patients
PremiumCompany AnnouncementsEblasakimab Shows Promise for AD Patients
5M ago
Aslan to present additional data from TREK-DX study during KOL event
Premium
The Fly
Aslan to present additional data from TREK-DX study during KOL event
5M ago
ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event
Premium
Press Releases
ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100